by Russell McAllister 03-27-2020
Bold Therapeutics announced that recent developments have suggested the potential utility of its lead drug BOLD-100 as a novel antiviral agent.Read more
Russell McAllister 03-27-2020
Bold Therapeutics announced that it has received clearance from Health Canada to initiate a Phase 1b trial.
Mark Bazett 02-10-2020
Bold Therapeutics will be visiting with multiple collaborators, vendors and partners in Europe from March 2nd to 6th.